The approval of *Cobenfy* (xanomeline and trospium chloride) by the U.S. Food and Drug Administration (FDA) in September 2024 represents a groundbreaking advancement in the treatment of schizophrenia. This drug, developed by **Karuna Therapeutics** and marketed by **Bristol Myers Squibb**, offers a novel approach for managing schizophrenia symptoms, which could lead to improved outcomes for […]